Posted in | News | Gold | Copper | Molybdenum

Carmax Mining Releases Assay Results from Eaglehead Property

Canadian company, Carmax Mining announced that it has obtained the assay results from 16 of the 25 holes, which were drilled on the Bornite Zone and East Zone target regions of its Eaglehead Cu-Mo project in 2011. The Eaglehead Property is situated in northwestern British Columbia.

The entire project included a drilling of 8,300 m in 25 holes and assay results from the first 8 holes were announced on 7 December, 2011. The ACME labs of Vancouver assayed all the split diamond drill core samples from the 2011 project.

The Eaglehead Property features a minimum of six regions of porphyry style Cu-Mo mineralization that expanded to over 8 km along strike. The exploration program conducted in summer 2011 concentrated on two of these target regions, which are the Bornite Zone and the East Zone. Low grade silver and gold values are linked with Cu-Mo mineralization. The company will plan future drilling projects to further define the Bornite Zone and the East Zone and will also drill test the other four target regions of the Eaglehead Property.

Toronto-based company, Roscoe Postle Associates (RPA) will evaluate the mineral resources of these two regions in view of the results obtained from the 2011 project. The report is expected to be completed by April 2012.

The East Zone consists of about 10 sub-vertical zones of Cu-Mo mineralization in hydrothermally changed granodioritic rocks, while the Bornite Zone consists of about eight areas of Cu-Mo mineralization with similar direction to the East Zone.

Till date, the results show extensions to formerly known mineralized zones with Mo, Cu, Au, and Ag values. The grades ranged from 0.16% Cu to 3.33% Cu and drill core intervals ranged from 3 to 161 m.

The mineralized zones in both regions range in horizontal width from 5 to 80 m, and expand over 400 m at depth in mineralized and hydrothermally changed zones are about 700 to 800 m long and 500 m wide.

Source: http://www.carmaxmining.com/

Joel Scanlon

Written by

Joel Scanlon

Joel relocated to Australia in 1995 from the United Kingdom and spent five years working in the mining industry as an exploration geotechnician. His role involved utilizing GIS mapping and CAD software. Upon transitioning to the North Coast of NSW, Australia, Joel embarked on a career as a graphic designer at a well-known consultancy firm. Subsequently, he established a successful web services business catering to companies across the eastern seaboard of Australia. It was during this time that he conceived and launched News-Medical.Net. Joel has been an integral part of AZoNetwork since its inception in 2000. Joel possesses a keen interest in exploring the boundaries of technology, comprehending its potential impact on society, and actively engaging with AI-driven solutions and advancements.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Scanlon, Joel. (2019, February 18). Carmax Mining Releases Assay Results from Eaglehead Property. AZoMining. Retrieved on May 02, 2024 from https://www.azomining.com/News.aspx?newsID=5838.

  • MLA

    Scanlon, Joel. "Carmax Mining Releases Assay Results from Eaglehead Property". AZoMining. 02 May 2024. <https://www.azomining.com/News.aspx?newsID=5838>.

  • Chicago

    Scanlon, Joel. "Carmax Mining Releases Assay Results from Eaglehead Property". AZoMining. https://www.azomining.com/News.aspx?newsID=5838. (accessed May 02, 2024).

  • Harvard

    Scanlon, Joel. 2019. Carmax Mining Releases Assay Results from Eaglehead Property. AZoMining, viewed 02 May 2024, https://www.azomining.com/News.aspx?newsID=5838.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.